Listed on the Main Board of the Singapore Exchange in October 2005, C & O Pharmaceutical Technology (Holdings) Limited ("C&O") is an established and integrated pharmaceutical group in the People's Republic of China ("China" or "PRC"). Our business model spans the entire value chain in the pharmaceutical industry, from research and development ("R&D"), to manufacturing, as well as marketing and distribution of C&O Branded and third party pharmaceutical products via an extensive distribution network covering over 3,000 distributors and 300,000 clinics, pharmacies and hospitals across all parts of China.

Our product portfolio comprises C&O Branded products and Exclusive products, focusing primarily on anti-infective and gastrointestinal drugs, drugs for ageing adults, as well as other specialized drugs.

With a strong emphasis on R&D, we continually expand the range of our C&O Branded products with a deep pipeline of generic and patented drugs. At the same time, we relentlessly source for new pharmaceutical products to be carried under our extensive distribution network in China.

With an integrated business model, we offer one-stop solutions to other pharmaceutical companies both in China and outside of China with our contract research organisation ("CRO") and contract manufacturing organisation ("CMO") services, as well as product registration and distribution services.